Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 20.91% is 47% above its 5-year average of 14.21%, near the high end of its 5-year range (-18.22%–28.67%).
4.10% above its 12-month average of 20.09%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 15.06%.
NET PROFIT MARGIN
20.91%
NET PROFIT MARGIN AVG TTM
20.09%
NET PROFIT MARGIN AVG 3Y
18.63%
NET PROFIT MARGIN AVG 5Y
14.21%
NET PROFIT MARGIN AVG 10Y
10.69%
NET PROFIT MARGIN AVG 15Y
8.15%
NET PROFIT MARGIN AVG 20Y
-2.09%
CURRENT VS TTM AVG
+4.10%
CURRENT VS 3Y AVG
+12.23%
CURRENT VS 5Y AVG
+47.19%
CURRENT VS 10Y AVG
+95.62%
CURRENT VS 15Y AVG
+156.69%
CURRENT VS 20Y AVG
+1102.59%
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+8142.31%
vs the sector median at left
Neurocrine Biosciences, Inc.
Market Cap
$14.61B
Net Profit Margin
20.91%
TTM Avg
20.09%
3Y Avg
18.63%
5Y Avg
14.21%
Market Cap
$14.49B
Net Profit Margin
20.45%
TTM Avg
2.71%
3Y Avg
2.53%
5Y Avg
1.60%
Market Cap
$14.56B
Net Profit Margin
35.33%
TTM Avg
28.88%
3Y Avg
23.04%
5Y Avg
19.31%
Market Cap
$14.59B
Net Profit Margin
-5.96%
TTM Avg
-1.67%
3Y Avg
5.09%
5Y Avg
7.31%
Market Cap
$14.16B
Net Profit Margin
71.08%
TTM Avg
-67.82%
3Y Avg
-363.95%
5Y Avg
-2068.81%
Market Cap
$15.10B
Net Profit Margin
17.26%
TTM Avg
12.25%
3Y Avg
14.36%
5Y Avg
15.15%
Market Cap
$13.67B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2793.69%
5Y Avg
-3700.03%
Market Cap
$13.07B
Net Profit Margin
-97.64%
TTM Avg
-193.35%
3Y Avg
-1980.08%
5Y Avg
-2361.16%
Market Cap
$13.01B
Net Profit Margin
24.86%
TTM Avg
33.22%
3Y Avg
32.75%
5Y Avg
45.02%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. (NBIX) | $14.61B | 20.91% | 20.09% | 18.63% | 14.21% |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.49B | 20.45% | 2.71% | 2.53% | 1.60% |
| Exelixis, Inc. (EXEL)vs › | $14.56B | 35.33% | 28.88% | 23.04% | 19.31% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.59B | -5.96% | -1.67% | 5.09% | 7.31% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 71.08% | -67.82% | -363.95% | -2068.81% |
| Solventum Corporation (SOLV)vs › | $15.10B | 17.26% | 12.25% | 14.36% | 15.15% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.67B | 0.00% | 0.00% | -2793.69% | -3700.03% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.07B | -97.64% | -193.35% | -1980.08% | -2361.16% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 24.86% | 33.22% | 32.75% | 45.02% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.90B | 6.61% | 16.89% | 20.26% | 23.62% |
Operating Margin
23.4%
Net Profit Margin
20.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 15.06% |
| 2026-03-31 | 24.30% |
| 2025-12-31 | 19.08% |
| 2025-09-30 | 26.36% |
| 2025-06-30 | 15.64% |
| 2025-03-31 | 1.38% |
| 2024-12-31 | 16.43% |
| 2024-09-30 | 20.86% |
| 2024-06-30 | 11.01% |
| 2024-03-31 | 8.42% |
| 2023-12-31 | 28.67% |
| 2023-09-30 | 16.66% |
| 2023-06-30 | 21.10% |
| 2023-03-31 | -18.22% |
| 2022-12-31 | 21.60% |
| 2022-09-30 | 17.66% |
| 2022-06-30 | -4.47% |
| 2022-03-31 | 4.48% |
| 2021-12-31 | -2.34% |
| 2021-09-30 | 7.60% |
| 2021-06-30 | 14.64% |
| 2021-03-31 | 13.57% |
| 2020-12-31 | 140.34% |
| 2020-09-30 | -22.28% |
| 2020-06-30 | 26.32% |
| 2020-03-31 | 15.77% |
| 2019-12-31 | 13.93% |
| 2019-09-30 | 24.22% |
| 2019-06-30 | 27.98% |
| 2019-03-31 | -73.78% |
| 2018-12-31 | 13.75% |
| 2018-09-30 | 33.45% |
| 2018-06-30 | -6.10% |
| 2018-03-31 | -58.83% |
| 2017-12-31 | 7.29% |
| 2017-09-30 | -18.31% |
| 2017-06-30 | -946.88% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | -128.43% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | -6.03% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | -1457.81% |
| 2013-09-30 | -1526.89% |
| 2013-06-30 | -1676.99% |
| 2013-03-31 | -1654.11% |
| 2012-12-31 | 43.24% |
| 2012-09-30 | -32.90% |
| 2012-06-30 | -4.74% |
| 2012-03-31 | -7.86% |
| 2011-12-31 | 11.98% |
| 2011-09-30 | 75.38% |
| 2011-06-30 | 16.25% |
| 2011-03-31 | 23.03% |
| 2010-12-31 | 18.21% |
| 2010-09-30 | 23.07% |
| 2010-06-30 | -110.96% |
| 2010-03-31 | -1146.88% |
| 2009-12-31 | -1069.73% |
| 2009-09-30 | -1115.55% |
| 2009-06-30 | -2084.58% |
| 2009-03-31 | -2632.53% |
| 2008-12-31 | -3958.02% |
| 2008-09-30 | -2327.33% |
| 2008-06-30 | -2857.08% |
| 2008-03-31 | -1203.71% |
| 2007-12-31 | -24055.45% |
| 2007-09-30 | -5044.44% |
| 2007-06-30 | -54925.00% |
| 2007-03-31 | -24730.77% |
| 2006-12-31 | -155.85% |
| 2006-09-30 | -3644.60% |
| 2006-06-30 | -296.94% |
| 2006-03-31 | -132.99% |
| 2005-12-31 | -169.43% |
| 2005-09-30 | 40.39% |
| 2005-06-30 | -16.90% |
| 2005-03-31 | -158.72% |
| 2004-12-31 | -111.52% |
| 2004-09-30 | -4.75% |
| 2004-06-30 | -73.97% |
| 2004-03-31 | -73.08% |
| 2003-12-31 | 11.77% |
| 2003-09-30 | -33.61% |
| 2003-06-30 | -22.74% |
| 2003-03-31 | -35.50% |
| 2002-12-31 | -1000.18% |
| 2002-09-30 | -406.06% |
